{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:53:10Z","timestamp":1793994790816,"version":"4.8.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Significance Statement<\/jats:title>\n                    <jats:p>Although cytomegalovirus (CMV) infection is an important factor in the pathogenesis of kidney allograft rejection, previous studies have not determined the optimal CMV prevention strategy to avoid indirect effects of the virus. In this randomized trial involving 140 kidney transplant recipients, incidence of acute rejection at 12 months was not lower with valganciclovir prophylaxis (for at least 3 months) compared with preemptive therapy initiated after detection of CMV DNA in whole blood. However, prophylaxis was associated with a lower risk of subclinical rejection at 3 months. Although both regimens were effective in preventing CMV disease, the incidence of CMV DNAemia (including episodes with higher viral loads) was significantly higher with preemptive therapy. Further research with long-term follow-up is warranted to better compare the two approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal regimen for preventing cytomegalovirus (CMV) infection in kidney transplant recipients, primarily in reducing indirect CMV effects, has not been defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This open-label, single-center, randomized clinical trial of valganciclovir prophylaxis versus preemptive therapy included kidney transplant recipients recruited between June 2013 and May 2018. After excluding CMV-seronegative recipients with transplants from seronegative donors, we randomized 140 participants 1:1 to receive valganciclovir prophylaxis (900 mg, daily for 3 or 6 months for CMV-seronegative recipients who received a kidney from a CMV-seropositive donor) or preemptive therapy (valganciclovir, 900 mg, twice daily) that was initiated after detection of CMV DNA in whole blood (\u22651000 IU\/ml) and stopped after two consecutive negative tests (preemptive therapy patients received weekly CMV PCR tests for 4 months). The primary outcome was the incidence of biopsy-confirmed acute rejection at 12 months. Key secondary outcomes included subclinical rejection, CMV disease and DNAemia, and neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The incidence of acute rejection was lower with valganciclovir prophylaxis than with preemptive therapy (13%, 9\/70 versus 23%, 16\/70), but the difference was not statistically significant. Subclinical rejection at 3 months was lower in the prophylaxis group (13% versus 29%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.027). Both regimens prevented CMV disease (in 4% of patients in both groups). Compared with prophylaxis, preemptive therapy resulted in significantly higher rates of CMV DNAemia (44% versus 75%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and a higher proportion of patients experiencing episodes with higher viral load (\u22652000 IU\/ml), but significantly lower valganciclovir exposure and neutropenia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among kidney transplant recipients, the use of valganciclovir prophylaxis did not result in a significantly lower incidence of acute rejection compared with the use of preemptive therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registry Name and Registration Number<\/jats:title>\n                    <jats:p>Optimizing Valganciclovir Efficacy in Renal Transplantation (OVERT Study), ACTRN12613000554763.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.0000000000000090","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T10:01:52Z","timestamp":1675764112000},"page":"920-934","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients"],"prefix":"10.1681","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-598X","authenticated-orcid":false,"given":"Tomas","family":"Reischig","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital, Pilsen, Czech Republic"},{"name":"Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Vlas","sequence":"additional","affiliation":[{"name":"Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic"},{"name":"Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kacer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital, Pilsen, Czech Republic"},{"name":"Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyna","family":"Pivovarcikova","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9391-4247","authenticated-orcid":false,"given":"Daniel","family":"Lysak","sequence":"additional","affiliation":[{"name":"Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic"},{"name":"Department of Hematology and Oncology, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Nemcova","sequence":"additional","affiliation":[{"name":"Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic"},{"name":"Department of Molecular Genetic, Biopticka laboratory, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Drenko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Machova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital, Pilsen, Czech Republic"},{"name":"Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Bouda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital, Pilsen, Czech Republic"},{"name":"Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sedivcova","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetic, Biopticka laboratory, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Kormunda","sequence":"additional","affiliation":[{"name":"Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic"},{"name":"Division of Information Technologies and Statistics, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"issue":"6","key":"B1-20250823","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation."},{"issue":"9","key":"B2-20250823","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1111\/ajt.15371","article-title":"Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients","volume":"19","author":"L'Huillier","year":"2019","journal-title":"Am J Transplant."},{"issue":"10","key":"B3-20250823","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/infdis\/jit064","article-title":"Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients","volume":"207","author":"Courivaud","year":"2013","journal-title":"J Infect Dis."},{"issue":"5","key":"B4-20250823","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/cid\/ciaa125","article-title":"Donor graft cytomegalovirus serostatus and the risk of arterial and venous thrombotic events in seronegative recipients after non-thoracic solid organ transplantation","volume":"72","author":"Belga","year":"2021","journal-title":"Clin Infect Dis."},{"issue":"2","key":"B5-20250823","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcv.2006.01.015","article-title":"The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection","volume":"36","author":"Reischig","year":"2006","journal-title":"J Clin Virol."},{"issue":"11","key":"B6-20250823","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1681\/ASN.2013101052","article-title":"Cytomegalovirus-responsive gammadelta T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions","volume":"25","author":"Bachelet","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"B7-20250823","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med."},{"issue":"3","key":"B8-20250823","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/ajt.16883","article-title":"The negative impact of T cell-mediated rejection on renal allograft survival in the modern era","volume":"22","author":"Rampersad","year":"2022","journal-title":"Am J Transplant."},{"issue":"2","key":"B9-20250823","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ajt.15183","article-title":"Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: a paired kidney analysis","volume":"19","author":"Leeaphorn","year":"2019","journal-title":"Am J Transplant."},{"issue":"6","key":"B10-20250823","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3851\/IMP3129","article-title":"The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation","volume":"22","author":"Reischig","year":"2017","journal-title":"Antivir Ther."},{"issue":"5","key":"B11-20250823","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant."},{"issue":"2","key":"B12-20250823","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.07020714","article-title":"Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation","volume":"10","author":"Reischig","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B13-20250823","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12879-018-3493-y","article-title":"Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial","volume":"18","author":"Reischig","year":"2018","journal-title":"BMC Infect Dis."},{"issue":"1","key":"B14-20250823","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation","volume":"8","author":"Reischig","year":"2008","journal-title":"Am J Transplant."},{"issue":"9","key":"B15-20250823","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1681\/ASN.2012010100","article-title":"Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation","volume":"23","author":"Reischig","year":"2012","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B16-20250823","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial","volume":"8","author":"Kliem","year":"2008","journal-title":"Am J Transplant."},{"issue":"5","key":"B17-20250823","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/TP.0000000000002024","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial","volume":"102","author":"Witzke","year":"2018","journal-title":"Transplantation."},{"issue":"5","key":"B18-20250823","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/jiz181","article-title":"Prospective assessment of cytomegalovirus immunity in high-risk donor-seropositive\/recipient-seronegative liver transplant recipients receiving either preemptive therapy or antiviral prophylaxis","volume":"220","author":"Limaye","year":"2019","journal-title":"J Infect Dis."},{"issue":"6","key":"B19-20250823","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/cit945","article-title":"A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant","volume":"58","author":"Florescu","year":"2014","journal-title":"Clin Infect Dis."},{"issue":"10","key":"B20-20250823","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1111\/ajt.16714","article-title":"Febrile neutropenia after kidney transplantation","volume":"21","author":"Dube","year":"2021","journal-title":"Am J Transplant."},{"issue":"1","key":"B21-20250823","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin Infect Dis."},{"issue":"3","key":"B22-20250823","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jcv.2011.12.019","article-title":"Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis","volume":"53","author":"Boivin","year":"2012","journal-title":"J Clin Virol."},{"issue":"1","key":"B23-20250823","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1600-6143.2011.03766.x","article-title":"High incidence of anticytomegalovirus drug resistance Among D+R- kidney transplant recipients receiving preemptive therapy","volume":"12","author":"Couzi","year":"2012","journal-title":"Am J Transplant."},{"issue":"9","key":"B24-20250823","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients","volume":"6","author":"Khoury","year":"2006","journal-title":"Am J Transplant."},{"issue":"9","key":"B25-20250823","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant."},{"issue":"1","key":"B26-20250823","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis."},{"issue":"9","key":"B27-20250823","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15507","article-title":"Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy","volume":"19","author":"Reischig","year":"2019","journal-title":"Am J Transplant."},{"issue":"11","key":"B28-20250823","first-page":"1970","article-title":"Viral load and duration of BK polyomavirus viraemia determine renal graft fibrosis progression: histologic evaluation of late protocol biopsies","volume":"34","author":"Reischig","year":"2019","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B29-20250823","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/ajt.16189","article-title":"The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: a multicenter validation study in the modern era","volume":"21","author":"Nickeleit","year":"2021","journal-title":"Am J Transplant."},{"issue":"8","key":"B30-20250823","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis."},{"issue":"2","key":"B31-20250823","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.antiviral.2009.10.004","article-title":"A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes","volume":"85","author":"Chevillotte","year":"2010","journal-title":"Antivir Res."},{"issue":"1","key":"B32-20250823","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12967-016-0932-7","article-title":"Validation of an IFN\u03b3\/IL2 FluoroSpot assay for clinical trial monitoring","volume":"14","author":"Korber","year":"2016","journal-title":"J Transl Med."},{"issue":"3","key":"B33-20250823","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/ajt.16902","article-title":"Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic","volume":"22","author":"Reischig","year":"2022","journal-title":"Am J Transplant."},{"issue":"10","key":"B34-20250823","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/cir619","article-title":"Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival","volume":"53","author":"Dzabic","year":"2011","journal-title":"Clin Infect Dis."},{"issue":"5","key":"B35-20250823","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/ajt.13618","article-title":"Virus-specific CD8(+) T cells cross-reactive to donor-alloantigen are transiently present in the circulation of kidney transplant recipients infected with CMV and\/or EBV","volume":"16","author":"Heutinck","year":"2016","journal-title":"Am J Transplant."},{"issue":"8","key":"B36-20250823","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1681\/ASN.2020111558","article-title":"Missing self-induced microvascular rejection of kidney allografts: a population-based study","volume":"32","author":"Callemeyn","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B37-20250823","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3851\/IMP1879","article-title":"Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients","volume":"16","author":"Reischig","year":"2011","journal-title":"Antivir Ther."},{"issue":"11","key":"B38-20250823","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jama.2020.11865","article-title":"Preemptive therapy vs antiviral prophylaxis in cytomegalovirus-seronegative liver transplant recipients with seropositive donors-reply","volume":"324","author":"Singh","year":"2020","journal-title":"JAMA."},{"issue":"9","key":"B39-20250823","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1111\/ajt.12370","article-title":"Kidney allograft survival after acute rejection, the value of follow-up biopsies","volume":"13","author":"El Ters","year":"2013","journal-title":"Am J Transplant."},{"issue":"6","key":"B40-20250823","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1097\/TP.0000000000001216","article-title":"Inflammation in early kidney allograft surveillance biopsies with and without associated tubulointerstitial chronic damage as a predictor of fibrosis progression and development of de novo donor specific antibodies","volume":"101","author":"Garcia-Carro","year":"2017","journal-title":"Transplantation."},{"issue":"8","key":"B41-20250823","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/ajt.13781","article-title":"Easier control of late-onset cytomegalovirus disease following universal prophylaxis through an early antiviral immune response in donor-positive, recipient-negative kidney transplants","volume":"16","author":"Kaminski","year":"2016","journal-title":"Am J Transplant."},{"issue":"9","key":"B42-20250823","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant."},{"issue":"4","key":"B43-20250823","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/cid\/cix793","article-title":"Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis","volume":"66","author":"Natori","year":"2018","journal-title":"Clin Infect Dis."},{"issue":"9","key":"B44-20250823","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/cid\/ciz1209","article-title":"Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation: a prospective, interventional, multicenter clinical trial","volume":"71","author":"Jarque","year":"2020","journal-title":"Clin Infect Dis."},{"issue":"5","key":"B45-20250823","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/cid\/ciab574","article-title":"Immunoguided discontinuation of prophylaxis for cytomegalovirus disease in kidney transplant recipients treated with antithymocyte globulin: a randomized clinical trial","volume":"74","author":"Paez-Vega","year":"2022","journal-title":"Clin Infect Dis."},{"issue":"8","key":"B46-20250823","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/ajt.13252","article-title":"The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication","volume":"15","author":"Schachtner","year":"2015","journal-title":"Am J Transplant."},{"key":"B47-20250823","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcv.2015.12.012","article-title":"In vitro studies of the impact of maribavir on CMV-specific cellular immune responses","volume":"75","author":"Stachel","year":"2016","journal-title":"J Clin Virol."},{"issue":"9","key":"B48-20250823","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant."},{"issue":"1","key":"B49-20250823","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1681\/ASN.2020121753","article-title":"mTOR inhibitors prevent CMV infection through the restoration of functional \u03b1\u03b2 and \u03b3\u03b4 T cells in kidney transplantation","volume":"33","author":"Kaminski","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"suppl 2","key":"B50-20250823","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ajt.16982","article-title":"OPTN\/SRTR 2020 annual data report: kidney","volume":"22","author":"Lentine","year":"2022","journal-title":"Am J Transplant."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000000000090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:47:58Z","timestamp":1786132078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000000000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000000000000090","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"2022-08-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}